Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 21a - New Efforts towards Evidence-Informed Practice and Practice-Informed Research: Commentary on Recent Developments in the Pharmacologic Management of Personality Disorders

  • from Part V - Treatment
  • Edited by Carl W. Lejuez, University of Kansas, Kim L. Gratz, University of Toledo, Ohio
  • Book:
    The Cambridge Handbook of Personality Disorders
    Published online:
    24 February 2020
    Print publication:
    07 May 2020, pp 514-516

  • Summary

    This commentary focuses on the current state and recent developments within the field of research on drug treatments for borderline personality disorder. From an evidence-based medicine perspective, the relevance of the currently available evidence for clinical practice is critically discussed. Some research/practice gaps are highlighted, like polypharmacy and the widespread use of quetiapine, which both lack supporting, sufficiently reliable evidence. Sources for the lack of practically relevant research are outlined, and the example of recent research on Olanzapine for patients with borderline personality disorder is amplified. Last, new initiatives are presented which aim at improving the value of research, like the REWARD alliance, the AllTrials campaign, and the James Lind alliance that guide, inform, and support the design, conduct, and publication of studies that are of relevancy to consumers and clinicians, and have the potential to transform healthcare. Some first encouraging results of these endeavors are presented.